Bartter's syndrome—treatment with potassium, spironolactone and ACE‐inhibitor

Abstract. The treatment of Bartter's syndrome is fraught with difficulties, and there is no consensus concerning the pathogenetic mechanisms involved. Potassium depletion with hypokaliaemia is a dominant feature of the syndrome. In this case history, a 42‐year‐old woman suffering from Bartter's syndrome did not improve on several therapeutic trials. An impressive progress was noted, however, after intensive potassium repletion with subsequent potassium/spironolactone/ACE‐inhibitor treatment. After 24 months her condition was unchanged with normal and stable Se‐potassium concentration. 1989 Blackwell Publishing Ltd